Trenton, OH— November 5, 2020— ClinArk, Inc., a minority-owned clinical consulting firm focused on helping pharmaceutical companies and contract research organizations increase clinical trial awareness, access, and participation in clinical trials, recently announced that it would be seeking to invest a quarter of a million dollars into minority-owned businesses around the United States. ClinArk plans to partner with over 100 minority-owned businesses to increase clinical trial participation and trust within communities. This initiative comes at a time when many companies are struggling to stay open.
"At ClinArk, we believe it takes a village to solve problems," said Adam Brown, CEO at ClinArk. "As a minority, I understand the fears, but, as a researcher, I also understand the importance of having people from all walks of life participating in research. I created my company because I wanted minorities to see people that look like them help push medicine forward. That is important. I want ClinArk to be that brand in clinical research that minorities can relate to and feel like they can trust".
ClinArk aims to invest from January 2021 through December 2021. ClinArk will equip businesses with the tools necessary to help recruit patients in their surrounding communities.
If your company is interested in joining ClinArk's initiative, send an email to firstname.lastname@example.org.
About Clinark Inc.
ClinArk, founded in 2019, is a clinical consulting firm that helps sponsors and contract research organizations execute clinical feasibilities and recruit patients. ClinArk's mission is to increase clinical trial awareness, access, and participation around the world. We believe that our services should solve problems that help make the world a better place. That is why our service offering helps expand clinical trial access and awareness. We are dedicated to helping all communities gain access to clinical trials, no matter the zip code. For more information, please visit www.clinark.org or follow us on LinkedIn, Facebook, or Twitter.